Eli Lilly suit against Houston’s Empower Pharmacy is a battle over access to a multi-billion dollar market for weight loss ...

Eli Lilly’s legal actions against Empower Pharmacy and other compounding pharmacies come several months after the FDA ...

Eli Lilly gains analyst support after Phase 3 success. Bullish forecasts for obesity dominance and key earnings are set for ...

The triumph of Ozempic, Wegovy, and related drugs, including Lilly’s Zepbound, has set off a push toward the next frontier: a ...

Pharmacies told to stop making custom versions of Wegovy and Zepbound after shortages declared officially over ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

In this edition of Daily Dose, Dr. Lacy Anderson answers a viewer's question about what discounts are available for weight ...

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

As the FDA cracks down on compounded GLP-1 drugs like semaglutide and tirzepatide, the market for GLP-1 supplements is taking ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Novo Nordisk submitted an oral version of the weight-loss formulation of semaglutide (Wegovy) for FDA approval, according to ...